EP1924596A4 - Protéines de fusion avec l'albumine - Google Patents
Protéines de fusion avec l'albumineInfo
- Publication number
- EP1924596A4 EP1924596A4 EP06813242A EP06813242A EP1924596A4 EP 1924596 A4 EP1924596 A4 EP 1924596A4 EP 06813242 A EP06813242 A EP 06813242A EP 06813242 A EP06813242 A EP 06813242A EP 1924596 A4 EP1924596 A4 EP 1924596A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- fusion proteins
- albumin fusion
- albumin
- proteins
- fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70752105P | 2005-08-12 | 2005-08-12 | |
| US71238605P | 2005-08-31 | 2005-08-31 | |
| US73272405P | 2005-11-03 | 2005-11-03 | |
| US77691406P | 2006-02-28 | 2006-02-28 | |
| US78136106P | 2006-03-13 | 2006-03-13 | |
| US81018206P | 2006-06-02 | 2006-06-02 | |
| US81368206P | 2006-06-15 | 2006-06-15 | |
| PCT/US2006/029391 WO2007021494A2 (fr) | 2005-08-12 | 2006-07-31 | Proteines de fusion avec l'albumine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1924596A2 EP1924596A2 (fr) | 2008-05-28 |
| EP1924596A4 true EP1924596A4 (fr) | 2009-07-29 |
Family
ID=37758042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP06813242A Withdrawn EP1924596A4 (fr) | 2005-08-12 | 2006-07-31 | Protéines de fusion avec l'albumine |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1924596A4 (fr) |
| JP (1) | JP2009504157A (fr) |
| KR (1) | KR20080071119A (fr) |
| AU (1) | AU2006280312A1 (fr) |
| BR (1) | BRPI0614761A2 (fr) |
| CA (1) | CA2618476A1 (fr) |
| EC (1) | ECSP088262A (fr) |
| IL (1) | IL189246A0 (fr) |
| MA (1) | MA29836B1 (fr) |
| MX (1) | MX2008001865A (fr) |
| NO (1) | NO20081233L (fr) |
| TN (1) | TNSN08064A1 (fr) |
| WO (1) | WO2007021494A2 (fr) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| WO2001077137A1 (fr) | 2000-04-12 | 2001-10-18 | Human Genome Sciences, Inc. | Proteines de fusion d'albumine |
| US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| EP2277889B1 (fr) | 2001-12-21 | 2014-07-09 | Human Genome Sciences, Inc. | Protéines chimériques d'albumine et interféron beta |
| CA2554089C (fr) | 2004-02-09 | 2013-10-22 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
| EP1816201A1 (fr) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Facteur de coagulation VIIa modifié ayant une stabilité 'half-life' améliorée |
| WO2007146038A2 (fr) | 2006-06-07 | 2007-12-21 | Human Genome Sciences, Inc. | Protéines de fusion d'albumine |
| BRPI0716744A2 (pt) * | 2006-09-14 | 2016-10-04 | Human Genome Sciences Inc | proteínas de fusão de albumina |
| CN107011431B (zh) | 2007-01-30 | 2020-11-06 | 埃皮瓦克斯公司 | 调节性t细胞表位、组合物及其用途 |
| JP5685529B2 (ja) | 2008-06-13 | 2015-03-18 | プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダＰｒｏｙｅｃｔｏ Ｄｅ Ｂｉｏｍｅｄｉｃｉｎａ Ｃｉｍａ， Ｓ．Ｌ． | 生物学的活性を有する化合物の投与のための複合体 |
| JP2012515222A (ja) | 2009-01-16 | 2012-07-05 | テバ ファーマシューティカル インダストリーズ リミテッド | 組換えヒトアルブミン−ヒト顆粒球コロニー刺激因子融合タンパク質の安定な製剤 |
| US8716448B2 (en) | 2009-02-03 | 2014-05-06 | Amunix Operating Inc. | Coagulation factor VII compositions and methods of making and using same |
| ES2630253T3 (es) | 2009-02-11 | 2017-08-18 | Albumedix A/S | Variantes de albúmina y conjugados |
| KR20100100254A (ko) * | 2009-03-05 | 2010-09-15 | (주)바이오큐어팜 | 인간 혈청 알부민-팀프-2 융합 단백질과 항암제를 포함하는암의 예방 또는 치료용 조성물 |
| US8748380B2 (en) * | 2009-10-30 | 2014-06-10 | Novozymes Biopharma Dk A/S | Albumin variants |
| US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
| US8691771B2 (en) | 2010-05-21 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins for tissue repair |
| EP2682128B1 (fr) * | 2011-02-28 | 2017-11-08 | National Cerebral and Cardiovascular Center | Peptide natriurétique auriculaire ou peptide cérébral natriurétique pour le prévention de la métastase |
| CN104011072B (zh) | 2011-05-05 | 2018-10-12 | 阿尔布梅迪克斯医疗有限公司 | 白蛋白变体 |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| CA2838833A1 (fr) | 2011-06-10 | 2012-12-13 | Biogen Idec Ma Inc. | Composes pro-coagulants et leurs procedes d'utilisation |
| CA2811250C (fr) | 2011-10-21 | 2015-08-11 | Abbvie Inc. | Methodes de traitement du vhc |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| SE1450019A1 (sv) | 2011-10-21 | 2014-01-10 | Abbvie Inc | Förfaranden för att behandla HCV innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| EP2780364A2 (fr) | 2011-11-18 | 2014-09-24 | Eleven Biotherapeutics, Inc. | Protéines ayant une demi-vie et d'autres propriétés améliorées |
| US11370827B2 (en) | 2012-01-12 | 2022-06-28 | Bioverativ Therapeutics Inc. | Chimeric factor VIII polypeptides and uses thereof |
| PT3564260T (pt) | 2012-02-15 | 2023-01-18 | Bioverativ Therapeutics Inc | Composições de fator viii e métodos de produção e utilização das mesmas |
| EP2822577B1 (fr) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Protéines de facteur viii de recombinaison |
| ES2664328T3 (es) | 2012-03-16 | 2018-04-19 | Albumedix A/S | Variantes de albúmina |
| AU2013270682A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Procoagulant compounds |
| CA2875247A1 (fr) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Facteurs de coagulation chimeriques |
| CN103525695B (zh) * | 2012-07-04 | 2015-05-20 | 长沙中生众捷生物技术有限公司 | 便携式肾功能检测系统 |
| CN110054699A (zh) | 2012-07-11 | 2019-07-26 | 比奥贝拉蒂治疗公司 | 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途 |
| US10391152B2 (en) | 2012-10-18 | 2019-08-27 | Bioverativ Therapeutics Inc. | Methods of using a fixed dose of a clotting factor |
| BR112015010318A2 (pt) | 2012-11-08 | 2017-08-22 | Albumedix As | Variantes de albumina |
| RS64664B1 (sr) | 2013-02-15 | 2023-11-30 | Bioverativ Therapeutics Inc | Gen optimizovanog faktora viii |
| KR20150118123A (ko) | 2013-02-16 | 2015-10-21 | 노보자임스 바이오파마 디케이 에이/에스 | 약동학적 동물 모델 |
| US10588949B2 (en) | 2013-03-15 | 2020-03-17 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
| CN105392495A (zh) | 2013-06-28 | 2016-03-09 | 比奥根Ma公司 | 具有xten的凝血酶可裂解连接子和其用途 |
| TW202003554A (zh) | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| HUE057005T2 (hu) | 2013-09-25 | 2022-04-28 | Bioverativ Therapeutics Inc | Oszlopon történõ vírusinaktiváló eljárások |
| EP3065769A4 (fr) | 2013-11-08 | 2017-05-31 | Biogen MA Inc. | Composé de fusion procoagulant |
| DK3091997T5 (da) | 2014-01-10 | 2024-10-14 | Bioverativ Therapeutics Inc | Kimære faktor viii-proteiner og anvendelser deraf |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| EA201700181A1 (ru) | 2014-10-14 | 2017-09-29 | Галозим, Инк. | Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| MA40861A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
| BR112018002150A2 (pt) | 2015-08-03 | 2018-09-18 | Bioverativ Therapeutics Inc | proteínas de fusão do fator ix e métodos de fabricação e uso das mesmas |
| US10633428B2 (en) | 2015-08-20 | 2020-04-28 | Albumedix Ltd | Albumin variants and conjugates |
| ES2863278T3 (es) | 2015-10-02 | 2021-10-11 | Silver Creek Pharmaceuticals Inc | Proteínas terapéuticas biespecíficas para la reparación de tejidos |
| CN105254766B (zh) * | 2015-10-26 | 2018-10-16 | 中国航天员科研训练中心 | 机械生长因子MGF E domain肽在调控记忆相关基因和miRNA表达中的应用 |
| HRP20221089T1 (hr) | 2016-02-01 | 2022-11-25 | Bioverativ Therapeutics Inc. | Optimizirani geni faktora viii |
| EP3448392A4 (fr) | 2016-04-28 | 2020-01-15 | Emory University | Compositions thérapeutiques à base de nucléotides et nucléosides contenant un alcyne et utilisations associées |
| WO2018082758A1 (fr) | 2016-11-04 | 2018-05-11 | Aarhus Universitet | Identification et traitement de tumeurs caractérisées par une surexpression du récepteur fc néonatal |
| IL308416B2 (en) | 2016-12-02 | 2025-08-01 | Bioverativ Therapeutics Inc | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| US12257288B2 (en) | 2016-12-02 | 2025-03-25 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
| EP3562840A1 (fr) | 2016-12-16 | 2019-11-06 | Biogen MA Inc. | Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé |
| CR20190389A (es) | 2017-01-31 | 2019-11-26 | Bioverativ Therapeutics Inc | Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas |
| WO2018193033A1 (fr) * | 2017-04-20 | 2018-10-25 | Novo Nordisk A/S | Procédés de purification de protéines de fusion d'albumine |
| TWI904068B (zh) | 2017-08-09 | 2025-11-11 | 美商生物化學醫療公司 | 核酸分子及其用途 |
| WO2019152692A1 (fr) | 2018-02-01 | 2019-08-08 | Bioverativ Therapeutics, Inc. | Utilisation de vecteurs lentiviraux exprimant le facteur viii |
| BR112020022164A2 (pt) | 2018-05-18 | 2021-02-02 | Bioverativ Therapeutics Inc. | métodos de tratamento de hemofilia a |
| CA3104686A1 (fr) | 2018-07-03 | 2020-01-09 | Bristol-Myers Squibb Company | Formulations de fgf21 |
| CA3108799A1 (fr) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Molecules d'acide nucleique et leurs utilisations pour une therapie genique non virale |
| AU2019393880A1 (en) | 2018-12-06 | 2021-07-15 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor IX |
| WO2021067389A1 (fr) | 2019-09-30 | 2021-04-08 | Bioverativ Therapeutics Inc. | Formulations de vecteur lentiviral |
| EP4171657A1 (fr) | 2020-06-24 | 2023-05-03 | Bioverativ Therapeutics Inc. | Procédés pour retirer le facteur viii à l'état libre contenu dans des préparations de vecteurs lentiviraux modifiés pour exprimer ladite protéine |
| WO2022030580A1 (fr) * | 2020-08-06 | 2022-02-10 | 国立大学法人宮崎大学 | Nouveau dérivé d'adrénomédulline à action prolongée, son procédé de production, et son utilisation pharmaceutique |
| US12487299B2 (en) | 2022-06-20 | 2025-12-02 | Shanghai United Imaging Healthcare Co., Ltd. | Magnetic resonance imaging devices and radiation therapy systems including the magnetic resonance imaging devices |
| US20250333481A1 (en) * | 2022-10-11 | 2025-10-30 | Jcr Pharmaceuticals Co., Ltd. | Fusion protein of serum albumin and physiologically-active protein |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003060071A2 (fr) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
| WO2005003296A2 (fr) * | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
| WO2005077042A2 (fr) * | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060051859A1 (en) * | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
-
2006
- 2006-07-31 EP EP06813242A patent/EP1924596A4/fr not_active Withdrawn
- 2006-07-31 JP JP2008526056A patent/JP2009504157A/ja not_active Withdrawn
- 2006-07-31 WO PCT/US2006/029391 patent/WO2007021494A2/fr not_active Ceased
- 2006-07-31 KR KR1020087006077A patent/KR20080071119A/ko not_active Withdrawn
- 2006-07-31 MX MX2008001865A patent/MX2008001865A/es not_active Application Discontinuation
- 2006-07-31 AU AU2006280312A patent/AU2006280312A1/en not_active Abandoned
- 2006-07-31 CA CA002618476A patent/CA2618476A1/fr not_active Abandoned
- 2006-07-31 BR BRPI0614761-5A patent/BRPI0614761A2/pt not_active IP Right Cessation
-
2008
- 2008-02-04 IL IL189246A patent/IL189246A0/en unknown
- 2008-02-11 TN TNP2008000064A patent/TNSN08064A1/en unknown
- 2008-03-07 MA MA30727A patent/MA29836B1/fr unknown
- 2008-03-10 NO NO20081233A patent/NO20081233L/no not_active Application Discontinuation
- 2008-03-12 EC EC2008008262A patent/ECSP088262A/es unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003060071A2 (fr) * | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
| WO2005003296A2 (fr) * | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
| WO2005077042A2 (fr) * | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Proteines hybrides d'albumine |
Also Published As
| Publication number | Publication date |
|---|---|
| TNSN08064A1 (en) | 2009-07-14 |
| WO2007021494A3 (fr) | 2007-07-26 |
| MA29836B1 (fr) | 2008-10-03 |
| IL189246A0 (en) | 2008-08-07 |
| WO2007021494A2 (fr) | 2007-02-22 |
| KR20080071119A (ko) | 2008-08-01 |
| EP1924596A2 (fr) | 2008-05-28 |
| MX2008001865A (es) | 2008-04-15 |
| AU2006280312A1 (en) | 2007-02-22 |
| JP2009504157A (ja) | 2009-02-05 |
| CA2618476A1 (fr) | 2007-02-22 |
| NO20081233L (no) | 2008-05-09 |
| BRPI0614761A2 (pt) | 2009-05-19 |
| ECSP088262A (es) | 2008-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL189246A0 (en) | Albumin fusion proteins | |
| IL176894A0 (en) | Albumin fusion proteins | |
| IL222924A0 (en) | Albumin fusion proteins | |
| IL197580A0 (en) | Albumin fusion proteins | |
| PL1830872T3 (pl) | Białka fuzyjne | |
| GB0426397D0 (en) | Fusion proteins | |
| IL204839A0 (en) | Albumin fusion proteins | |
| ZA200801224B (en) | Albumin fusion proteins | |
| EP1858546A4 (fr) | Proteines hybrides modifiees de transferrine | |
| EP1594530A4 (fr) | Proteines hybrides d'albumine | |
| IL196889A0 (en) | Albumin-insulin fusion proteins | |
| ZA200709871B (en) | Interferon-IgG fusion | |
| EP1934372A4 (fr) | Proteines hybrides ssb-polymerase | |
| IL196674A0 (en) | Exendin fusion proteins | |
| GB0519965D0 (en) | Joint fusion peg | |
| GB0423974D0 (en) | Proteins | |
| PL1879909T3 (pl) | Roztwór albuminy pozbawiony cząsteczek stabilizatora | |
| HK1113581A (en) | Albumin fusion proteins | |
| GB0426399D0 (en) | Fusion proteins | |
| HK1131548A (en) | Albumin fusion proteins | |
| AU2005905300A0 (en) | Fusion Protein | |
| GB0511861D0 (en) | Proteins | |
| GB0423002D0 (en) | Proteins | |
| GB0513505D0 (en) | Proteins | |
| GB0514788D0 (en) | Proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20080312 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1113581 Country of ref document: HK |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20090626 |
|
| 17Q | First examination report despatched |
Effective date: 20100108 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20120201 |
|
| DAX | Request for extension of the european patent (deleted) | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1113581 Country of ref document: HK |